AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 11737964 — intervention group
Group type: COMPARATOR
Intervention: Control subjects (nondiabetic elderly)
Number of subjects: 15
Study 9312760 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythropoietin (EPO) 4000 U per week
Number of subjects: 0
Study 9312760 — intervention group
Group type: COMPARATOR
Intervention: Control group (hemodialyzed patients without EPO)
Number of subjects: 0
Study 8349825 — intervention group
Group type: EXPERIMENTAL
Intervention: lovastatin (40 mg b.i.d.) + low cholesterol diet (mean 246 mg/d)
Number of subjects: 12
Study 8349825 — intervention group
Group type: EXPERIMENTAL
Intervention: lovastatin (40 mg b.i.d.) + high cholesterol diet (mean 1,071 mg/d)
Number of subjects: 12
Study 8349825 — intervention group
Group type: COMPARATOR
Intervention: low cholesterol diet alone
Number of subjects: 12
Study 8349825 — intervention group
Group type: COMPARATOR
Intervention: high cholesterol diet alone
Number of subjects: 12
Study 2872813 — intervention group
Group type: COMPARATOR
Intervention: Terazosin (5, 10, or 20 mg once daily for four weeks)
Number of subjects: 0
Study 2872813 — intervention group
Group type: COMPARATOR
Intervention: Terazosin (dose titration until maximum 20 mg)
Number of subjects: 0
Study 2872813 — intervention group
Group type: COMPARATOR
Intervention: Prazosin (dose titration until maximum 20 mg)
Number of subjects: 0
Study 2872813 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 31145384 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric Training (PT)
Number of subjects: 2
Study 29565235 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery training group practicing four team-level tactics by imagining team actions in specific game situations, three times a week for 4 weeks.
Number of subjects: 0
Study 29565235 — intervention group
Group type: COMPARATOR
Intervention: No imagery training (control group).
Number of subjects: 0
Study 28556481 — intervention group
Group type: EXPERIMENTAL
Intervention: Reciprocity prime
Number of subjects: 0
Study 28556481 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 0
Study 26231610 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sodium bicarbonate therapy for 24 months
Number of subjects: 380
Study 26231610 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 24 months
Number of subjects: 380
Study 24245948 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive education based on the Explore Transplant series of educational materials
Number of subjects: 500
Study 24245948 — intervention group
Group type: COMPARATOR
Intervention: Standard-of-care ('usual') transplant education
Number of subjects: 500
Study 24245948 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive education
Number of subjects: 500
Study 21145041 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0777 3 mg b.i.d. (n = 18)
Number of subjects: 60
Study 21145041 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-0777 8 mg b.i.d. (n = 21)
Number of subjects: 60
Study 21145041 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 21)
Number of subjects: 60
Study 18922091 — intervention group
Group type: EXPERIMENTAL
Intervention: LLLT + NMES (7 J for 10 min)
Number of subjects: 5
Study 18922091 — intervention group
Group type: EXPERIMENTAL
Intervention: LLLT + NMES (3 J for 5 min)
Number of subjects: 5
Study 18922091 — intervention group
Group type: COMPARATOR
Intervention: NMES only (Control)
Number of subjects: 5
Study 18922091 — intervention group
Group type: COMPARATOR
Intervention: Comparison between LLLT trials and Control
Number of subjects: 5
Study 16542187 — intervention group
Group type: EXPERIMENTAL
Intervention: Inositol
Number of subjects: 17
Study 16542187 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 12951904 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A in a single megadose
Number of subjects: 46
Study 12951904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 11077134 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (6.25-12.5 mg)
Number of subjects: 320
Study 11077134 — intervention group
Group type: COMPARATOR
Intervention: Losartan (12.5-25 mg)
Number of subjects: 320
Study 9228488 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensively-treated patients with gestational diabetes mellitus
Number of subjects: 550
Study 9228488 — intervention group
Group type: COMPARATOR
Intervention: Gestational diabetes mellitus patients who delivered at term
Number of subjects: 550
Study 9228488 — intervention group
Group type: EXPERIMENTAL
Intervention: Gestational diabetes mellitus patients who delivered preterm
Number of subjects: 550
Study 8394646 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP vaccine
Number of subjects: 97
Study 8394646 — intervention group
Group type: COMPARATOR
Intervention: DTwP vaccine
Number of subjects: 97
Study 2887553 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine
Number of subjects: 90
Study 2887553 — intervention group
Group type: COMPARATOR
Intervention: Anticholinergics
Number of subjects: 90
Study 29230548 — intervention group
Group type: EXPERIMENTAL
Intervention: cis100 + RT (conventional radiotherapy with cisplatin 100 mg/m2 on days 1, 22, and 43)
Number of subjects: 62
Study 29230548 — intervention group
Group type: COMPARATOR
Intervention: cis40 + ART (accelerated radiotherapy with cisplatin weekly 40 mg/m2)
Number of subjects: 62
Study 28454835 — intervention group
Group type: EXPERIMENTAL
Intervention: Nateglinide and Valsartan
Number of subjects: 9306
Study 25460855 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone discontinuation (group 1)
Number of subjects: 112
Study 25460855 — intervention group
Group type: COMPARATOR
Intervention: No amiodarone discontinuation (group 2)
Number of subjects: 112
Study 24159603 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH gel (16 units)
Number of subjects: 23
Study 24159603 — intervention group
Group type: EXPERIMENTAL
Intervention: ACTH gel (32 units)
Number of subjects: 23
Study 21390311 — intervention group
Group type: EXPERIMENTAL
Intervention: Favorable SNP variants (CC, AA, TT)
Number of subjects: 253
Study 21390311 — intervention group
Group type: EXPERIMENTAL
Intervention: IP-10 below 150 pg/mL among genotype 1 infected carriers of favorable alleles
Number of subjects: 253
Study 21390311 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline IP-10 and C genotype at rs12979860
Number of subjects: 253
Study 18991255 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightweight (poliglecaprone‐polypropylene composite)
Number of subjects: 392
Study 18991255 — intervention group
Group type: COMPARATOR
Intervention: Heavyweight (polypropylene)
Number of subjects: 392
Study 18991255 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 392
Study 16447057 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 (1.2 pmol kg(‐1) min(‐1))
Number of subjects: 14
Study 16447057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 14530465 — intervention group
Group type: EXPERIMENTAL
Intervention: 99mTc-P829 scintigraphy (approximately equal to 740 MBq)
Number of subjects: 44
Study 12578881 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin use
Number of subjects: 641
Study 12578881 — intervention group
Group type: COMPARATOR
Intervention: Nonuse of statins
Number of subjects: 641
Study 10488976 — intervention group
Group type: EXPERIMENTAL
Intervention: Cricopharyngeal myotomy
Number of subjects: 125
Study 10488976 — intervention group
Group type: COMPARATOR
Intervention: No myotomy (Control)
Number of subjects: 125
Study 8760715 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral wedge resection (performed 6 months to 1 year prior)
Number of subjects: 15
Study 8760715 — intervention group
Group type: COMPARATOR
Intervention: Oral glucose tolerance test (100 g)
Number of subjects: 15
Study 8760715 — intervention group
Group type: COMPARATOR
Intervention: Control group (normally menstruating women of similar age and BMI, n = 15)
Number of subjects: 15
Study 1887969 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anaesthesia by retrobulbar block
Number of subjects: 20
Study 1887969 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 20
Study 6347995 — intervention group
Group type: EXPERIMENTAL
Intervention: Misonidazole 2.5 gm/m2 once a week for six weeks (total dose 15 gm/m2) plus radiotherapy (5100 cGy over 6 weeks)
Number of subjects: 245
Study 6347995 — intervention group
Group type: COMPARATOR
Intervention: Conventional radiation therapy (6000 cGy/6-7 weeks) plus BCNU (80 mg/m2 on days 3, 4, 5, repeated q 8 weeks for 2 years)
Number of subjects: 245
Study 3469101 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg slow-release formulation of diclofenac sodium
Number of subjects: 0
Study 29618101 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 32
Study 29618101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 32
Study 28895878 — intervention group
Group type: EXPERIMENTAL
Intervention: Oat betaglucans (1.53 g of β‐glucan) administered three times daily before meals for two weeks
Number of subjects: 14
Study 28895878 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Plac) administered three times daily before meals for two weeks
Number of subjects: 14
Study 26571899 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous electrical acupoint stimulation (TEAS) applied to bilateral Hegu (LI 4) and Neiguan (PC 6) for 30 min, with dense‐disperse wave, 2 Hz/100 Hz in frequency.
Number of subjects: 40
Study 26571899 — intervention group
Group type: COMPARATOR
Intervention: Sham-stimulation applied to the acupoints with the lamp on but without electric current output.
Number of subjects: 40
Study 24175595 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration training
Number of subjects: 58
Study 24175595 — intervention group
Group type: EXPERIMENTAL
Intervention: Eccentric training
Number of subjects: 58
Study 24175595 — intervention group
Group type: COMPARATOR
Intervention: Wait-and-see approach
Number of subjects: 58
Study 21396122 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem solving therapy
Number of subjects: 0
Study 21396122 — intervention group
Group type: COMPARATOR
Intervention: Supportive counselling
Number of subjects: 0
Study 21396122 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioural exercise
Number of subjects: 0
Study 21396122 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducation
Number of subjects: 0
Study 21396122 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of interventions
Number of subjects: 0
Study 18478129 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous moxifloxacin (400 mg daily) for 5 days starting within 36 hours after stroke onset
Number of subjects: 80
Study 18478129 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 5 days starting within 36 hours after stroke onset
Number of subjects: 80
Study 18478129 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous moxifloxacin (400 mg daily) for 5 days
Number of subjects: 80
Study 18478129 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 5 days
Number of subjects: 80
Study 18478129 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous moxifloxacin (400 mg daily)
Number of subjects: 80
Study 18478129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 18478129 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment groups
Number of subjects: 80
Study 16509866 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alpha‐2a (40 kDa)/ribavirin for 24 weeks (group A)
Number of subjects: 491
Study 16509866 — intervention group
Group type: EXPERIMENTAL
Intervention: peginterferon alpha‐2a (40 kDa)/ribavirin for 48 weeks (group B)
Number of subjects: 491
Study 16509866 — intervention group
Group type: COMPARATOR
Intervention: no treatment for 72 weeks (group C)
Number of subjects: 491
Study 12483413 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET positive patients
Number of subjects: 46
Study 12483413 — intervention group
Group type: EXPERIMENTAL
Intervention: High standardized uptake value (SUV)
Number of subjects: 46
Study 12483413 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET imaging
Number of subjects: 46
Study 12483413 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET imaging in untreated patients
Number of subjects: 46
Study 10686040 — intervention group
Group type: EXPERIMENTAL
Intervention: Bambuterol (10 mg oral solution once daily)
Number of subjects: 155
Study 10686040 — intervention group
Group type: COMPARATOR
Intervention: Terbutaline (0.075 mg/kg oral solution three times daily)
Number of subjects: 155
Study 8994466 — intervention group
Group type: EXPERIMENTAL
Intervention: PCA (patient-controlled intravenous opioid analgesic administration)
Number of subjects: 75
Study 8994466 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen
Number of subjects: 75
Study 8994466 — intervention group
Group type: COMPARATOR
Intervention: codeine
Number of subjects: 75
Study 8398438 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-amoxiclav (250 mg amoxycillin plus 125 mg clavulanic acid, eight-hourly)
Number of subjects: 79
Study 8398438 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V (250 mg phenoxymethylpenicillin, six-hourly)
Number of subjects: 79
Study 3510944 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy with chlorambucil and cisplatin
Number of subjects: 369
Study 3510944 — intervention group
Group type: COMPARATOR
Intervention: Sequential therapy with chlorambucil and cisplatin
Number of subjects: 369
Study 3510944 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line treatment with cisplatin after initial chlorambucil failure
Number of subjects: 369
Study 3510944 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy
Number of subjects: 369
Study 3510944 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgically documented complete response rate
Number of subjects: 369
Study 3510944 — intervention group
Group type: EXPERIMENTAL
Intervention: Survival rates
Number of subjects: 369
Study 31518482 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV immunization
Number of subjects: 1200
Study 31518482 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV DNA testing
Number of subjects: 1200
Study 31518482 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean viral load for OBI-positive cases
Number of subjects: 1200
Study 31518482 — intervention group
Group type: EXPERIMENTAL
Intervention: Testing of parents of OBI-positive children
Number of subjects: 1200
Study 29984710 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrowns made of lithium disilicate ceramic (IPS e.max CAD)
Number of subjects: 40
Study 29984710 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrowns made of Solidex microhybrid composite
Number of subjects: 40
Study 29984710 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrowns made of Grandia microhybrid composite
Number of subjects: 40
Study 29984710 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group IN)
Number of subjects: 40
Study 27052296 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-brain radiotherapy combined with sodium glycididazole at a dose of 700mg/m² intravenous infusion 30 minutes before radiotherapy, three times a week
Number of subjects: 64
Study 27052296 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-brain radiotherapy combined with sodium glycididazole
Number of subjects: 64
Study 27052296 — intervention group
Group type: COMPARATOR
Intervention: Whole-brain radiotherapy
Number of subjects: 64
Study 24813752 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined CoQ10 and clomiphene citrate
Number of subjects: 101
Study 24813752 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate alone
Number of subjects: 101
Study 23044701 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfacalcidol (active form of vitamin D3)
Number of subjects: 107
Study 23044701 — intervention group
Group type: COMPARATOR
Intervention: Control group (no alfacalcidol)
Number of subjects: 107
Study 21400753 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycloferon combined with lamivudine
Number of subjects: 0
Study 21400753 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycloferon combined with a-interferon
Number of subjects: 0
Study 21400753 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycloferon
Number of subjects: 0
Study 18321512 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromagnetic stimulation
Number of subjects: 0
Study 18321512 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 0
Study 16390366 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g/day omega-3 fatty acids
Number of subjects: 16
Study 16390366 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.4 g/day omega-3 fatty acids
Number of subjects: 16
Study 16390366 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.8 g/day omega-3 fatty acids
Number of subjects: 16
Study 16390366 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined groups of omega-3 fatty acids
Number of subjects: 16
Study 12563203 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 447
Study 12563203 — intervention group
Group type: COMPARATOR
Intervention: Carotid angioplasty and stenting (CAS)
Number of subjects: 447
Study 10994618 — intervention group
Group type: EXPERIMENTAL
Intervention: H. pylori eradication treatment (n = 10)
Number of subjects: 20
Study 10994618 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 20
Study 9093339 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (500 micrograms)
Number of subjects: 20
Study 9093339 — intervention group
Group type: COMPARATOR
Intervention: Histamine
Number of subjects: 20
Study 9093339 — intervention group
Group type: COMPARATOR
Intervention: Adenosine monophosphate (AMP)
Number of subjects: 20
Study 9093339 — intervention group
Group type: COMPARATOR
Intervention: Histamine and AMP
Number of subjects: 20
Study 8237525 — intervention group
Group type: EXPERIMENTAL
Intervention: Pefloxacin
Number of subjects: 96
Study 8237525 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone
Number of subjects: 96
Study 4006647 — intervention group
Group type: EXPERIMENTAL
Intervention: ursodeoxycholic acid, 800 mg/day
Number of subjects: 39
Study 4006647 — intervention group
Group type: EXPERIMENTAL
Intervention: ursodeoxycholic acid, 400 mg/day
Number of subjects: 39
Study 4006647 — intervention group
Group type: EXPERIMENTAL
Intervention: chenodeoxycholic acid, 750 mg/day
Number of subjects: 39
Study 4006647 — intervention group
Group type: EXPERIMENTAL
Intervention: chenodeoxycholic acid, 375 mg/day
Number of subjects: 39
Study 4006647 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 39
Study 30930022 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-4774 (2, 10, or 40 yeast units) with Tenofovir Disoproxil Fumarate (TDF) 300 mg daily
Number of subjects: 195
Study 30930022 — intervention group
Group type: COMPARATOR
Intervention: TDF 300 mg daily
Number of subjects: 195
Study 30930022 — intervention group
Group type: EXPERIMENTAL
Intervention: GS-4774
Number of subjects: 195
Study 28507171 — intervention group
Group type: EXPERIMENTAL
Intervention: big ET‐1 (≤300 pmol/min)
Number of subjects: 10
Study 28507171 — intervention group
Group type: COMPARATOR
Intervention: intravenous placebo
Number of subjects: 10
Study 25252699 — intervention group
Group type: EXPERIMENTAL
Intervention: Ospemifene 60 mg/day
Number of subjects: 919
Study 25252699 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 919
Study 23897954 — intervention group
Group type: EXPERIMENTAL
Intervention: Luminal A-like (LA-like)
Number of subjects: 1951
Study 23897954 — intervention group
Group type: EXPERIMENTAL
Intervention: Luminal B-like (LB-like)
Number of subjects: 1951
Study 23897954 — intervention group
Group type: EXPERIMENTAL
Intervention: HER2 positive
Number of subjects: 1951
Study 23897954 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple negative (TN)
Number of subjects: 1951
Study 21877761 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipragliflozin (ASP1941), doses ranging from 5-600 mg, administered once daily for 10 days
Number of subjects: 0
Study 19236490 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive craniopuncture therapy
Number of subjects: 465
Study 19236490 — intervention group
Group type: COMPARATOR
Intervention: Conservative treatment
Number of subjects: 465
Study 16552540 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Licochalcone A (LicA)
Number of subjects: 0
Study 16552540 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 0
Study 12940503 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (0-500 mg/70 kg, per os)
Number of subjects: 6
Study 12940503 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (0-500 mg/70 kg, per os) combined with naloxone (0.15 mg/70 kg, intramuscularly)
Number of subjects: 6
Study 12940503 — intervention group
Group type: COMPARATOR
Intervention: Naloxone (0.15 mg/70 kg, intramuscularly)
Number of subjects: 6
Study 10617748 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP vaccine
Number of subjects: 327
Study 10617748 — intervention group
Group type: EXPERIMENTAL
Intervention: DTaP vaccines
Number of subjects: 327
Study 9020562 — intervention group
Group type: EXPERIMENTAL
Intervention: beta‐2‐microglobulin concentration in serum
Number of subjects: 50
Study 9020562 — intervention group
Group type: COMPARATOR
Intervention: beta‐2‐microglobulin concentration in urine
Number of subjects: 50
Study 9020562 — intervention group
Group type: COMPARATOR
Intervention: treatment
Number of subjects: 50
Study 1549149 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose methotrexate (10 mg/m²)
Number of subjects: 127
Study 1549149 — intervention group
Group type: COMPARATOR
Intervention: Very-low-dose methotrexate (5 mg/m²)
Number of subjects: 127
Study 1549149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 127
Study 3983884 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline (10 mg/ml)
Number of subjects: 17
Study 3983884 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine theophyllinate (50 mg/ml)
Number of subjects: 17
Study 3983884 — intervention group
Group type: EXPERIMENTAL
Intervention: Aminophylline (50 mg/ml)
Number of subjects: 17
Study 3983884 — intervention group
Group type: EXPERIMENTAL
Intervention: Diprophylline (125 mg/ml)
Number of subjects: 17
Study 3983884 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 17